Market Place
Sourcing Support
OS` drug stopped lung cancer from returning in 3rd of patients
16 Jan 2025 //
FIERCE BIOTECH
OS Therapies to Attend 43rd Annual J.P. Morgan Conference
02 Jan 2025 //
BUSINESSWIRE
OS Therapies Announces Closing of $6 Million Private Placement
31 Dec 2024 //
BUSINESSWIRE
OS Therapy Partner with B2i Digital for Biotech Invest Engagement
26 Dec 2024 //
BUSINESSWIRE
OS Therapies Announces Pricing of $6 Million Private Placement
24 Dec 2024 //
BUSINESSWIRE
OS Therapies Reports Q3 2024 Results and Business Update
15 Nov 2024 //
BUSINESSWIRE
OS Therapies Appoints 2 Industry Veterans to Board of Directors
28 Oct 2024 //
BUSINESSWIRE
OS Therapies to Present at the LD Micro Main Event XVII
24 Oct 2024 //
BUSINESSWIRE
OS Therapies To Participate In 2024 Maxim Healthcare Virtual Summit
17 Oct 2024 //
BUSINESSWIRE
OS Therapies Announces Development Of Novel Tunable ADC Candidates
13 Sep 2024 //
BUSINESSWIRE
OS Therapies to Present at H.C. Wainwright Annual Global Investment Conference
05 Sep 2024 //
BUSINESSWIRE
OS Therapies Completes Last Dose In OST-HER2 Osteosarcoma Trial
29 Aug 2024 //
BUSINESSWIRE
OS Therapies Clarifies CUSIP of Common Stock
22 Aug 2024 //
BUSINESSWIRE
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
22 Aug 2024 //
BUSINESSWIRE
OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
19 Aug 2024 //
BUSINESSWIRE
OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board
02 Aug 2024 //
BUSINESSWIRE
OS Therapies Refiles For $6M IPO
01 Aug 2024 //
FIERCE BIOTECH
OS Therapies Prices IPO On NYSE American, To Trade As "OSTX"
31 Jul 2024 //
BUSINESSWIRE
OS Therapies Reports Positive Data For OST-HER2 In Breast Cancer
24 Jul 2024 //
BUSINESSWIRE
OS Therapies` Positive Resected, Recurrent Osteosarcoma Phase 2b Update
03 Jun 2024 //
BUSINESSWIRE
OS Therapies Announces Full Enrollment in PhIIb Clinical Trial AOST-2121
26 Sep 2023 //
BUSINESSWIRE
OS Therapies Announces Enrollment of Remaining Patients in Phase IIb of OST-HER2
27 Jan 2022 //
PRNEWSWIRE
OS Therapies Receives Rare Pediatric Disease Designation (RDD) OST-HER2
03 Nov 2021 //
PRNEWSWIRE
OS Therapies doses first subject in Phase IIb osteosarcoma therapy trial
25 Oct 2021 //
CLINICALTRIALSARENA
OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2
22 Oct 2021 //
PRNEWSWIRE
OS Therapies Completes $6 Million Series A Funding Round
20 Apr 2021 //
PRNEWSWIRE
OS Therapies Completes $6 Million Series A Funding Round
19 Apr 2021 //
PRNEWSWIRE
OS Therapies Receives Trial Approval From Children`s Oncology Group AOST2121
26 Jan 2021 //
PRNEWSWIRE
Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2
19 Jan 2021 //
GLOBENEWSWIRE
